1. Home
  2. SNPX

SNPX

Synaptogenix Inc.

Logo Synaptogenix Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Founded: 2012 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 5.1M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 49.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -29.50 EPS Growth: N/A
52 Week Low/High: $3.52 - $47.00 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: